Bristol Myers Squibb reports positive Phase 3 results for Camzyos in adolescents with oHCM
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Iktos will deploy its AI-driven tools to accelerate the identification of optimized small-molecule candidates against a currently undisclosed oncology target
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Subscribe To Our Newsletter & Stay Updated